TPST

Tempest Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website empesttx.com
Employees(FY) 19
ISIN US87978U1088

Performance

-8.36%

1W

-5.07%

1M

-15.87%

3M

-3.34%

6M

-27.73%

YTD

+55.88%

1Y

Profile

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Advanced Technical Analysis

Technical Analysis of TPST 2024-05-10

Overview:

In analyzing the technical indicators for the last 5 days of TPST stock, we will delve into the trends, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining key metrics such as moving averages, MACD, RSI, Stochastic Oscillator, Bollinger Ban...

See more ...

Recent News & Updates

2024-05-09 04:29
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-04-26 04:05
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-04-08 20:00
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting(Globenewswire)
2024-04-03 20:00
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications(Globenewswire)
2024-03-19 09:53
TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q4 2023(Investorplace)
2024-03-19 04:25
Tempest Reports Year End 2023 Financial Results and Provides Business Update(Globenewswire)
2024-03-11 20:00
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types(Globenewswire)
2024-03-05 03:30
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting(Globenewswire)
2024-02-25 19:00
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference(Globenewswire)
2024-02-02 03:30
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-01-05 03:05
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2023-12-01 03:15
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2023-11-19 19:00
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference(Globenewswire)
2023-11-08 04:17
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update(Globenewswire)
2023-10-11 20:25
Why Is Tempest Therapeutics (TPST) Stock Down 35% Today?(Investorplace)
2023-10-11 04:29
TPST Stock: 7 Things to Know About Tempest Therapeutics(Investorplace)
2023-10-10 20:01
Tempest Adopts Limited Duration Stockholder Rights Plan(Globenewswire)
2023-10-10 20:00
Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study(Globenewswire)
2023-10-10 19:41
Why Is Tempest Therapeutics (TPST) Stock Up 325% Today?(Investorplace)
2023-10-10 04:05
Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma(Globenewswire)
2023-09-18 20:00
Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development(Yahoo Finance)
2023-09-04 20:00
Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)
2023-08-10 04:13
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update(Yahoo Finance)
2023-07-18 20:00
Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together(Yahoo Finance)
2023-05-31 04:05
Tempest to Present at the Jefferies Global Healthcare Conference(Yahoo Finance)
2023-05-25 05:00
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers(Yahoo Finance)
2023-05-19 04:05
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Yahoo Finance)
2023-05-10 04:15
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update(Yahoo Finance)
2023-04-27 20:00
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma(Yahoo Finance)
2023-04-27 04:58
Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma(Yahoo Finance)

Page 1 of 3

previousnext